Effect of Lamotrigine on Cognition in NF1
- Registration Number
- NCT02256124
- Lead Sponsor
- Erasmus Medical Center
- Brief Summary
The purpose of this study is to determine whether lamotrigine can improve cognitive and neurophysiological deficits in adolescents with Neurofibromatosis type 1.
- Detailed Description
Cognitive deficits in the autosomal dominant disorder Neurofibromatosis type 1 (NF1) typically consist of a lower than average IQ, impaired visual-spatial learning, attention problems and impaired executive functioning. These deficits have a substantial influence on the daily life of pediatric and adolescent individuals with NF1. One of the key underlying mechanisms of these deficits is an increased gamma-aminobutyric acid (GABA)-ergic inhibition and a subsequent decrease in synaptic plasticity. The ENCORE laboratory has recently shown that loss of the NF1-gene is associated with attenuated function of the hyperpolarization-activated cyclic nucleotide-gated channel 1 (HCN1). These channels, enriched in membranes of inhibitory interneurons, play an important role in the pathophysiology underlying the cognitive deficits in NF1. Lamotrigine, an HCN-agonist, restored function of HCN1, together with the electrophysiological and visual-spatial learning deficits in Nf1-mice. Thus, lamotrigine is a novel candidate drug for treating cognitive deficits associated with NF1.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 41
- NF1 patients with a genetically confirmed diagnosis
- Age 12-17.5 years at inclusion
- Oral and written informed consent by parents and assent from participants
- Segmental NF1
- Severe hearing problems or deafness
- Severe visual problems or blindness
- Use of the following medication, as of interaction with lamotrigine: phenytoin, carbamazepine, phenobarbital, primidon, rifampicin, atazanavir/ritonavir, lopinavir/ritonavir, oxcarbazepine, topiramate, oral contraceptive pill including stop-week (estrogen and progesterone) and valproic acid during 3 months before inclusion.
- Use of psycho-active medication other than methylphenidate
- Previous allergic reactions to anti-epileptic drugs
- Epilepsy or epilepsy in the past
- Suicidal thoughts or behaviour
- Renal insufficiency
- Liver insufficiency
- Pregnancy
- Brain tumour or other brain pathology potentially influencing the outcome measures
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Placebo tablets during 28 consecutive weeks, with identical appearance to lamotrigine tablets, mimicking the lamotrigine dosing schedule. Lamotrigine Lamotrigine Lamotrigine during 28 consecutive weeks: * 8 weeks dose-increase phase: from 25mg once daily to 100mg twice daily * 18 weeks target-dose phase: 100mg twice daily * 2 weeks decline-phase: 100mg once daily.
- Primary Outcome Measures
Name Time Method Performance intelligence quotient (change from baseline) Baseline and 26 weeks Assessed by the Wechsler Intelligence Scales for Children - third edition (WISC-III).
- Secondary Outcome Measures
Name Time Method Attention problems (change from baseline) Baseline, 10 weeks, 26 weeks and 52 weeks Assessed by a parent rated ADHD-questionnaire, the ADHD-vragenlijst (AVL).
Executive functioning (change from baseline) Baseline, 26 weeks and 52 weeks Assessed by the Behavior Rating Inventory for Executive Function parent questionnaire (BRIEF).
Short intracortical inhibition (SICI) (change from baseline) Baseline and 10 weeks Assessed by paired pulse transcranial magnetic stimulation (ppTMS).
Long-term potentiation-like plasticity (change from baseline) Baseline and 10 weeks Assessed by paired associative stimulation (PAS) using transcranial magnetic stimulation (TMS).
Visual-spatial working memory (change from baseline) Baseline and 26 weeks Assessed by the Paired Associative Learning (PAL) task of the Cambridge Neuropsychological Test Automated Battery (CANTAB).
Visual perception (change from baseline) Baseline and 26 weeks Assessed by the Motor Free Visual Perception Test - third edition (MVPT-3).
Sustained attention (change from baseline) Baseline and 26 weeks Assessed by the Sustained Attention DOTS (SA-DOTS) of the Amsterdam Neuropsychological Tasks (ANT).
Visual-motor integration (change from baseline) Baseline and 26 weeks Assessed by the Beery-Buktenica Developmental Task of Visual Motor Integration - sixth edition (Beery-VMI-6).
Fine motor coordination (change from baseline) Baseline and 26 weeks Assessed by the Grooved Pegboard Test.
Trial Locations
- Locations (3)
University Hospital Leuven
🇧🇪Leuven, Belgium
Erasmus Medical Center
🇳🇱Rotterdam, South Holland, Netherlands
Hospital Sant Joan de Deu
🇪🇸Barcelona, Spain